Page 123 - 《中国药房》2022年18期

et al. Evaluation of cyclosporine pharmacokinetic，moni‐ [23] GUADA M，BELOQUI A，KUMAR M N V R，et al. Re‐
toring，and dosing parameters for GVHD prophylaxis in formulating Cyclosporine A（CsA）：more than just a life
hematopoietic stem cell transplant（HSCT）recipients[J]. cycle management strategy[J]. J Control Release，2016，
Iran J Pharm Res，2019，18（Suppl 1）：302-314. 225：269-282.
[12] LIDDICOAT A M，LAVELLE E C. Modulation of innate [24] BARTEN M J，TARNOK A，GARBADE J，et al. Pharma‐
immunity by cyclosporine A[J]. Biochem Pharmacol， codynamics of T-cell function for monitoring immunosup‐
2019，163：472-480. pression[J]. Cell Prolif，2007，40（1）：50-63.
[13] CAPRON A，HAUFROID V，WALLEMACQ P. Intra- [25] SERHAT INALOZ H，OZTURK S，AKCALI C，et al.
cellular immunosuppressive drugs monitoring：a step for‐ Low-dose and short-term cyclosporine treatment in pa‐
ward towards better therapeutic efficacy after organ trans‐ tients with chronic idiopathic urticaria：a clinical and im‐
plantation? [J]. Pharmacol Res，2016，111：610-618. munological evaluation[J]. J Dermatol，2008，35（5）：
[14] LEMAITRE F，VETHE N T，D’AVOLIO A，et al. Measu- 276-282.
ring intracellular concentrations of calcineurin inhibitors： [26] ZAHN A，SCHOTT N，HINZ U，et al. Immunomonitoring
expert consensus from the international association of of nuclear factor of activated T cells-regulated gene ex‐
therapeutic drug monitoring and clinical toxicology expert pression：the first clinical trial in liver allograft recipients
panel[J]. Ther Drug Monit，2020，42（5）：665-670. [J]. Liver Transpl，2011，17（4）：466-473.
[15] FALCK P，ASBERG A，GULDSETH H，et al. Declining [27] MILLÁN O，RUIZ P，FORTUNA V，et al. Nuclear factor
of activated T cells as potential pharmacodynamic bio‐
intracellular T-lymphocyte concentration of cyclosporine a
marker for the risk of acute and subclinical rejection in de
precedes acute rejection in kidney transplant recipients[J].
novo liver recipients[J]. Liver Int，2020，40（4）：931-946.
Transplantation，2008，85（2）：179-184.
[28] SOMMERER C，BROCKE J，BRUCKNER T，et al. Im‐
[16] CRETTOL S，VENETZ J P，FONTANA M，et al. Inf-
proved pulse wave velocity and renal function in individua-
luence of ABCB1 genetic polymorphisms on cyclosporine
lized calcineurin inhibitor treatment by immunomonito-
intracellular concentration in transplant recipients[J]. Phar‐
ring：the randomized controlled calcineurin inhibitor-
macogenet Genomics，2008，18（4）：307-315.
sparing trial[J]. Transplantation，2018，102（3）：510-520.
[17] VANHOVE T，ANNAERT P，KUYPERS D R. Clinical
[29] SOMMERER C，GIESE T. Nuclear factor of activated T
determinants of calcineurin inhibitor disposition：a mecha‐
cells-regulated gene expression as predictive biomarker of
nistic review[J]. Drug Metab Rev，2016，48（1）：88-112.
personal response to calcineurin inhibitors[J]. Ther Drug
[18] BARBARI A G，MASRI M A，STEPHAN A G，et al. Cy‐
Monit，2016，38（Suppl 1）：S50-S56.
closporine lymphocyte maximum level：a new alternative
[30] CHRISTIANS U，SEWING K F. Cyclosporin metabolism
for cyclosporine monitoring in kidney transplantation[J].
in transplant patients[J]. Pharmacol Ther，1993，57（2/3）：
Exp Clin Transplant，2005，3（1）：293-300.
291-345.
[19] SANQUER S，SCHWARZINGER M，MAURY S，et al.
[31] WU Q H，KUCA K. Metabolic pathway of cyclosporine A
Calcineurin activity as a functional index of immunosup‐
and its correlation with nephrotoxicity[J]. Curr Drug
pression after allogeneic stem-cell transplantation[J].
Metab，2019，20（2）：84-90.
Transplantation，2004，77（6）：854-858.
[32] HRYNIEWIECKA E，ŻEGARSKA J，ŻOCHOWSKA D，
[20] CARUSO R，PERICO N，CATTANEO D，et al. Whole-
et al. Cyclosporine metabolites’metabolic ratios may be
blood calcineurin activity is not predicted by cyclosporine
markers of cardiovascular disease in kidney transplant re‐
blood concentration in renal transplant recipients[J]. Clin
cipients treated with cyclosporine A-based immunosup‐
Chem，2001，47（9）：1679-1687.
pression regimens[J]. Cardiovasc Toxicol，2019，19（3）：
[21] FUKUDO M，YANO I，MASUDA S，et al. Pharmacody‐ 255-263.
namic analysis of tacrolimus and cyclosporine in living- [33] ZEGARSKA J，HRYNIEWIECKA E，ZOCHOWSKA D，
donor liver transplant patients[J]. Clin Pharmacol Ther， et al. Higher concentrations of cyclosporine metabolites in
2005，78（2）：168-181. liver transplant recipients with a history of viral and bac-
[22] PAI S Y，FRUMAN D A，LEONG T，et al. Inhibition of terial infections[J]. Transplant Proc，2020，52（8）：2503-
calcineurin phosphatase activity in adult bone marrow 2506.
transplant patients treated with cyclosporine A[J]. Blood， （收稿日期：2022-02-25 修回日期：2022-08-17）
1994，84（11）：3974-3979. （编辑：邹丽娟）

中国药房 2022年第33卷第18期 China Pharmacy 2022 Vol. 33 No. 18 ·2289·